From the Neuroradiology Section (G.C., C.A., L.M.P., W.C., A.d.B., A.S., À.R.).
Department of Radiology, and Servei de Neurologia-Neuroimmunologia (J.S.-G., X.M.). Centre d'Esclerosi Múltiple de Catalunya, Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
AJNR Am J Neuroradiol. 2022 Apr;43(4):534-539. doi: 10.3174/ajnr.A7474. Epub 2022 Mar 24.
Acute inflammatory activity of MS lesions is traditionally assessed through contrast-enhanced T1-weighted MR images. The aim of our study was to determine whether a qualitative evaluation of non-contrast-enhanced SWI of new T2-hyperintense lesions might help distinguish acute and chronic lesions and whether it could be considered a possible alternative to gadolinium-based contrast agents for this purpose.
Serial MR imaging studies from 55 patients with MS were reviewed to identify 169 new T2-hyperintense lesions. Two blinded neuroradiologists determined their signal pattern on SWI, considering 5 categories (hypointense rings, marked hypointensity, mild hypointensity, iso-/hyperintensity, indeterminate). Two different blinded neuroradiologists evaluated the presence or absence of enhancement in postcontrast T1-weighted images of the lesions. The Fisher exact test was used to determine whether each category of signal intensity on SWI was associated with gadolinium enhancement.
The presence of hypointense rings or marked hypointensity showed a strong association with the absence of gadolinium enhancement (< .001), with a sensitivity of 93.0% and a specificity of 82.9%. The presence of mild hypointensity or isohyperintensity showed a strong association with the presence of gadolinium enhancement (< .001), with a sensitivity of 68.3% and a specificity of 99.2%.
A qualitative analysis of the signal pattern on SWI of new T2-hyperintense MS lesions allows determining the likelihood that the lesions will enhance after administration of a gadolinium contrast agent, with high specificity albeit with a moderate sensitivity. While it cannot substitute for the use of contrast agent, it can be useful in some clinical settings in which the contrast agent cannot be administered.
传统上,通过对比增强 T1 加权磁共振图像评估 MS 病变的急性炎症活动。我们的研究目的是确定对新 T2 高信号病变的非对比增强 SWI 进行定性评估是否有助于区分急性和慢性病变,以及它是否可以作为钆基造影剂的替代方法。
回顾性分析 55 例 MS 患者的连续 MRI 检查,以确定 169 个新的 T2 高信号病变。两位盲法神经放射科医生根据 SWI 的信号模式确定病变的信号强度,分为 5 个类别(低信号环、明显低信号、轻度低信号、等/高信号、不确定)。两位不同的盲法神经放射科医生评估病变增强后 T1 加权图像的存在或不存在。Fisher 确切检验用于确定 SWI 上每个信号强度类别是否与钆增强相关。
低信号环或明显低信号的存在与无钆增强有很强的关联(<0.001),具有 93.0%的敏感性和 82.9%的特异性。轻度低信号或等/高信号的存在与钆增强有很强的关联(<0.001),具有 68.3%的敏感性和 99.2%的特异性。
对新 T2 高信号 MS 病变的 SWI 信号模式进行定性分析,可以确定病变在给予钆造影剂后增强的可能性,特异性高但敏感性中等。虽然它不能替代造影剂的使用,但在某些不能使用造影剂的临床情况下可能有用。